Legend Biotech (LEGN) vs Parabilis Medicines (PBLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Legend Biotech is the larger company by market cap ($3.68 billion vs $3.47 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LEGN | PBLS |
|---|---|---|
| Share price | $18.94 | $28.10 |
| Market cap | $3.68B | $3.47B |
| 1-day change | +1.23% | +0.04% |
| YTD return | -13.94% | — |
| 1-year return | -41.91% | — |
| 5-year return | -63.96% | — |
| Forward P/E | 18.04 | — |
| EPS (TTM) | $-0.52 | $-9.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03B | — |
| Revenue growth (YoY) | +64.04% | — |
| Net income (latest FY) | $-296.80M | — |
| Gross margin | 61.41% | — |
| Operating margin | -13.27% | — |
| Net margin | -28.85% | — |
| 52-week high | $37.50 | $42.49 |
| 52-week low | $16.24 | $24.51 |
| Distance from 52-week high | -49.49% | -33.87% |
| Analyst consensus | buy | none |
| Avg. price target upside | +145.51% | +48.58% |
| Average volume | 2.37M | 690.91K |
| Shares outstanding | 194.49M | 121.95M |
| Employees | 3,200 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
LEGN vs PBLS FAQ
Which is bigger, Legend Biotech or Parabilis Medicines?
Legend Biotech (LEGN) is larger, with a market capitalization of $3.68B compared with $3.47B for Parabilis Medicines (PBLS).
Are Legend Biotech and Parabilis Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.